The sixth leading cancer diagnosis in U.S. men and women[2], NHL has more than 30 sub-types, each featuring unique treatment choices and challenges.[3] To further educate people with Non-Hodgkin’s Lymphomas and empower them to make informed treatment decisions for their disease, the National Comprehensive Cancer Network , through support of the NCCN Foundation , has published NCCN Guidelines for Patients and NCCN Quick Guide series for NHL, specifically for Diffuse Large B-Cell, Follicular, Mantle Cell, and Peripheral T-Cell Lymphoma. The NCCN Guidelines for Patients : Diffuse Large B-Cell Lymphoma and Follicular Lymphoma are made possible, in part, through generous sponsorship from The Leukemia & Lymphoma Society.
